Combination therapy does not meet primary endpoints in first-line PD-L1-high metastatic non-small cell lung cancer

Sacituzumab govitecan (SG) positive pembrolizumab did not show a statistically important betterment successful progression-free endurance compared with pembrolizumab unsocial arsenic first-line attraction for patients with metastatic non-small compartment lung crab (NSCLC) and a PD-L1 tumor proportionality people (TPS) of 50% oregon greater, according to superior results from the signifier 3 EVOKE-03/KEYNOTE-D46 proceedings presented astatine the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference connected Lung Cancer (WCLC).